(NASDAQ: SWTX) Springworks Therapeutics's forecast annual revenue growth rate of 64.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.41%.
Springworks Therapeutics's revenue in 2025 is $191,589,000.On average, 6 Wall Street analysts forecast SWTX's revenue for 2025 to be $24,791,776,614, with the lowest SWTX revenue forecast at $23,268,330,784, and the highest SWTX revenue forecast at $26,880,988,112. On average, 5 Wall Street analysts forecast SWTX's revenue for 2026 to be $42,501,815,660, with the lowest SWTX revenue forecast at $35,838,819,621, and the highest SWTX revenue forecast at $53,745,490,337.
In 2027, SWTX is forecast to generate $64,724,941,207 in revenue, with the lowest revenue forecast at $48,766,752,463 and the highest revenue forecast at $84,770,430,954.